DDInter364 DDInter1185
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents; however, it is still used as monotherapy or in combination with [hydrochlorothiazide]. Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.
Chlorpropamide {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Methyldopa
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Methyldopa
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Chlorpropamide {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Levodopa
Levodopa {u} (Compound) resembles {v} (Compound) Methyldopa
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Levodopa
Levodopa {u} (Compound) resembles {v} (Compound) Methyldopa
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dopamine
Dopamine {u} (Compound) resembles {v} (Compound) Methyldopa
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dopamine
Dopamine {u} (Compound) resembles {v} (Compound) Methyldopa
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Chlorpropamide (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Methyldopa (Compound)
Chlorpropamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Methyldopa (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Methyldopa
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methyldopa
Chlorpropamide (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Levodopa (Compound) and Levodopa (Compound) resembles Methyldopa (Compound)
Chlorpropamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Levodopa (Compound) and Levodopa (Compound) resembles Methyldopa (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Methyldopa (Compound)
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Methyldopa (Compound)
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa